アフェレシス - 世界市場の考察、競合情勢、市場予測（2030年）

世界のアフェレシスの市場規模は、2022年に22億3,066万米ドル、2030年までに36億7,155万米ドルに達し、予測期間（2022年～2028年）にCAGRで8.75%の成長が見込まれています。市場は、鎌状赤血球貧血、血液がんなどの血液疾患の有病率の増加、さまざまなバイオ製薬企業による原血漿の需要の増加、予測期間（2024年～2030年）におけるアフェレシスシステムの発売と承認の増加などの要因により、活況を呈する見込みです。

アフェレシスの市場力学

アフェレシス市場の注目すべき促進要因の中でも、血液疾患の有病率の増加がアフェレシス市場を加速させる大きな要因となっています。

例えば、世界保健機関（WHO）（2023）が発表したデータによれば、貧血は幼児と妊婦の両方に影響を及ぼす深刻な世界の公衆衛生問題です。WHOの推計は近年の研究と一致しており、世界中で5歳未満の子供の約42％、妊婦の約40％が貧血であると考えられています。

さらに、National Cancer Institute（NCI）（2022）によると、2022年に米国で約6万650人の白血病患者が新たに発生すると推定されています。

Global Blood Therapeutics（2020）のレポートによると、2019年に欧州に住む5万2,000人以上が鎌状赤血球症に罹患しています。同じ資料によると、この疾患は母集団より約25～30年寿命を短くし、主にアフリカ系、地中海系、南アジア系の人々が罹患する傾向があります。

今後、血液疾患の有病率の増加は、アフェレシスデバイスの需要を増加させ、2022年～2028年の調査期間にアフェレシスデバイスの全体的な市場成長を促進すると予測されます。

アフェレシス市場に関連するもう1つの主な促進要因は、さまざまな疾患の管理と治療に向けた革新的なアフェレシスデバイスの開発です。

例えば、2022年5月、Baxter International Inc.は同社の次世代プラットフォームの最新バージョンであるPrisMax 2のグローバル発売を発表しました。PrisMax 2は、治療的血漿交換療法やその他の臓器の支持療法向けに設計されており、また集中治療室（ICU）特有の需要に対応できる柔軟性を病院に提供します。

さらに2020年4月、Terumo BCT, Inc.とMarker Therapeutics AGは、Terumo BCTのSpectra Optia（TM）アフェレシスシステムとMarker TherapeuticsのD2000 Adsorption Cartridgeを組み合わせて、COVID-19が確認された18歳以上の患者を治療することについて、米国FDAが緊急使用許可（EUA）を出したと発表しました。

しかし、アフェレシス治療に伴う高いコストとさまざまなリスクが、アフェレシス市場の成長抑制要因として作用する可能性があります。

アフェレシス市場はCOVID-19パンデミック中、プラス成長が報告されました。COVID-19患者の増加により、血小板数、フィブリノゲン、Dダイマー、プロトロンビン時間（PT）、活性化部分トロンボプラスチン時間（APTT）などのさまざまな凝固パラメーターが重症感染者の合併症として発見されたため、血漿療法に関する広範な用途が与えられました。COVID-19で感染した患者には回復期血漿療法が行われています。また、Lancet Journalで公開された記事によると、2020年5月28日から2022年6月15日の間に、回復期に登録された患者1万6,287人のうち1万1,558人（71％）が回復期血漿の投与を受ける資格がありました。CP療法では、感染症から回復したばかりの患者の体内から血漿を採取し、その採取した血漿をリスクのある人の体内に注入します。このように、パンデミック中にこれらすべての要因が世界のアフェレシス市場の成長にプラスの影響を与えました。

多くの人々がワクチン接種を受け、医療部門を含む産業全体の活動が再開されたことで、アフェレシス市場は2024年～2030年の予測期間にさらなるプラス成長が見込まれます。

当レポートでは、世界のアフェレシス市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 アフェレシス市場レポートのイントロダクション

第2章 アフェレシス市場のエグゼクティブサマリー

• 調査範囲
• 市場の概要
• 競合の評価

第3章 規制分析

• 米国
• 欧州
• 日本
• 中国

第4章 アフェレシス市場の主な要因の分析

• アフェレシス市場の促進要因
  • 血液疾患の有病率の増加
  • バイオ医薬品企業からの原血漿の需要の高まり
  • アフェレシス処置に関連する有利な償還政策と資金提供
• アフェレシス市場の抑制要因と課題
  • アフェレシス治療に伴う高いコスト
  • アフェレシス治療に伴うリスク
• アフェレシス市場の機会
  • 小児向けに特別に設計された新しいアフェレシス治療法のイノベーションと研究開発の急増
  • リポタンパクアフェレシスのコストの削減、治療の広範な利用可能性

第5章 アフェレシス市場のポーターのファイブフォース分析

第6章 アフェレシス市場に対するCOVID-19の影響分析

第7章 アフェレシス市場のレイアウト

• 製品タイプ別
  • アフェレシス機械
  • 使い捨て用品
• 技術別
  • 遠心分離
  • 膜ろ過
• 処置別
  • 白血球除去療法
  • 血漿交換
  • 血小板交換
  • 赤血球除去療法
  • その他
• 用途別
  • 腎疾患
  • 血液疾患
  • 神経疾患
  • 自己免疫疾患
• 地域別
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 アフェレシス市場：世界の企業シェア分析 - 主要3～5社

第9章 アフェレシス市場の企業と製品のプロファイル

• Braun Melsungen AG
• Asahi Kasei Corporation
• Fresenius Kabi AG
• Haemonetics Corporation
• Terumo Corporation
• Baxter International
• Kaneka Corporation
• Sumitomo Bakelite Company Limited
• Medica SPA
• Nikkiso Co., Ltd.
• Cerus Corporation
• Miltenyi Biotec B.V.& Co. KG
• Haier Inc.
• Otsuka Holdings

第10章 KOLの見解

第11章 プロジェクトのアプローチ

第12章 DelveInsightについて

第13章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: COVID-19 Impact Analysis on Apheresis Market
• Table 3: Apheresis Market in Global (2021-2030)
• Table 4: Apheresis Market in Global by Product Type (2021-2030)
• Table 5: Apheresis Market in Global by Technology (2021-2030)
• Table 6: Apheresis Market in Global by Procedure (2021-2030)
• Table 7: Apheresis Market in Global by Application (2021-2030)
• Table 8: Apheresis Market in Global by Geography (2021-2030)
• Table 9: Apheresis Market in North America (2021-2030)
• Table 10: Apheresis Market in North America by Country (2021-2030)
• Table 11: Apheresis Market in the US (2021-2030)
• Table 12: Apheresis Market in Canada (2021-2030)
• Table 13: Apheresis Market in Mexico (2021-2030)
• Table 14: Apheresis Market in Europe (2021-2030)
• Table 15: Apheresis Market in Europe by Country (2021-2030)
• Table 16: Apheresis Market in France (2021-2030)
• Table 17: Apheresis Market in Germany (2021-2030)
• Table 18: Apheresis Market in the United Kingdom (2021-2030)
• Table 19: Apheresis Market in Italy (2021-2030)
• Table 20: Apheresis Market in Spain (2021-2030)
• Table 21: Apheresis Market in Rest of Europe (2021-2030)
• Table 22: Apheresis Market in APAC (2021-2030)
• Table 23: Apheresis Market in APAC by Country (2021-2030)
• Table 24: Apheresis Market in China (2021-2030)
• Table 25: Apheresis Market in Japan (2021-2030)
• Table 26: Apheresis Market in India (2021-2030)
• Table 27: Apheresis Market in Australia (2021-2030)
• Table 28: Apheresis Market in South Korea (2021-2030)
• Table 29: Apheresis Market in Rest of APAC (2021-2030)
• Table 30: Apheresis Market in Rest of World (2021-2030)
• Table 31: Apheresis Market in RoW by Region (2021-2030)
• Table 32: Apheresis Market in Middle East (2021-2030)
• Table 33: Apheresis Market in Africa (2021-2030)
• Table 34: Apheresis Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: COVID-19 Impact Analysis on Apheresis Market
• Figure 3: Apheresis Market in Global (2021-2030)
• Figure 4: Apheresis Market in Global by Product Type (2021-2030)
• Figure 5: Apheresis Market in Global by Technology (2021-2030)
• Figure 6: Apheresis Market in Global by Procedure (2021-2030)
• Figure 7: Apheresis Market in Global by Application (2021-2030)
• Figure 8: Apheresis Market in Global by Geography (2021-2030)
• Figure 9: Apheresis Market in North America (2021-2030)
• Figure 10: Apheresis Market in North America by Country (2021-2030)
• Figure 11: Apheresis Market in the US (2021-2030)
• Figure 12: Apheresis Market in Canada (2021-2030)
• Figure 13: Apheresis Market in Mexico (2021-2030)
• Figure 14: Apheresis Market in Europe (2021-2030)
• Figure 15: Apheresis Market in Europe by Country (2021-2030)
• Figure 16: Apheresis Market in France (2021-2030)
• Figure 17: Apheresis Market in Germany (2021-2030)
• Figure 18: Apheresis Market in the United Kingdom (2021-2030)
• Figure 19: Apheresis Market in Italy (2021-2030)
• Figure 20: Apheresis Market in Spain (2021-2030)
• Figure 21: Apheresis Market in Rest of Europe (2021-2030)
• Figure 22: Apheresis Market in APAC (2021-2030)
• Figure 23: Apheresis Market in APAC by Country (2021-2030)
• Figure 24: Apheresis Market in China (2021-2030)
• Figure 25: Apheresis Market in Japan (2021-2030)
• Figure 26: Apheresis Market in India (2021-2030)
• Figure 27: Apheresis Market in Australia (2021-2030)
• Figure 28: Apheresis Market in South Korea (2021-2030)
• Figure 29: Apheresis Market in Rest of APAC (2021-2030)
• Figure 30: Apheresis Market in Rest of World (2021-2030)
• Figure 31: Apheresis Market in RoW by Region (2021-2030)
• Figure 32: Apheresis Market in Middle East (2021-2030)
• Figure 33: Apheresis Market in Africa (2021-2030)
• Figure 34: Apheresis Market in South America (2021-2030)
• Figure 35: Market Drivers
• Figure 36: Market Barriers
• Figure 37: Marker Opportunities
• Figure 38: PORTER'S Five Force Analysis

Apheresis Market By Product Type (Apheresis Machine And Disposable), By Technology (Centrifugation And Membrane Filtration), By Procedure (Leukapheresis, Plasmapheresis, Plateletpheresis, Erythrocytapheresis And Others), By Application (Renal Disorders, Hematological Disorders, Neurological Disorders, Automune Disorders, And Others), by geography is estimated to register growth at a remarkable CAGR forecast during 2024-2030 owing to the rising increasing prevalence of hematological disorders and rise in the requirement of source plasma by various biopharmaceutical companies

The global apheresis market was valued at USD 2,230.66 million in 2022 and is estimated to grow at a CAGR of 8.75% during the forecast period (2022-2028) to reach USD 3,671.55 million by 2030. The apheresis market is slated to witness prosperity owing to factors such as the increasing prevalence of hematological disorders such as sickle cell anemia, blood cancers among others, the rise in the requirement of source plasma by various biopharmaceutical companies and an increase in the launch and approval of apheresis systems during the forecast period (2024-2030).

Apheresis Market Dynamics:

Among the noteworthy drivers of the apheresis market, the rising prevalence of hematological disorders turns out to be the major factor for accelerating the apheresis market.

For example, as per the data published by the World Health Organization (2023), anemia is a serious global public health problem that affects both young children and pregnant women. WHO estimates are in accordance with recent studies, and observes that about 42% of children less than 5 years of age and about 40% of the pregnant women are anemic globally.

Moreover, as per the National Cancer Institute 2022 (NCI), it has been estimated that there will be around 60,650 new cases of leukemia in the United States in 2022.

The report by Global Blood Therapeutics 2020 showed that sickle cell disease affected more than 52,000 people living in Europe in 2019. As per the same source, the condition carries a life expectancy of about 25 to 30 years below the general population and tends to predominantly affect the African, Mediterranean and the South Asian descent people.

Henceforth, the increasing prevalence of hematological disorders, will increase the demand for apheresis devices, which is anticipated to propel the overall market growth of the apheresis devices in the study period of 2022 - 2028.

Another major driver pertaining to the apheresis market is the development of innovative apheresis devices for the management and treatment of various diseases.

For example, in May 2022, Baxter International Inc., announced the global launch of PrisMax 2, the latest version of the company's next-generation platform. PrisMax 2 is designed for therapeutic plasma exchange therapy and other organ support therapies, while providing hospitals the flexibility to meet the unique demands of the intensive care unit (ICU).

Furthermore, in April 2020, Terumo BCT, Inc. and Marker Therapeutics AG announced that the US FDA has issued Emergency Use Authorization for the use of Terumo BCT's Spectra Optia(TM) Apheresis System combined with Marker Therapeutics' D2000 Adsorption Cartridge to treat patients 18 years of age or older with confirmed COVID-19.

However, high costs and the various risks associated with apheresis treatment may act as restraining factors for the apheresis market growth.

The apheresis market reported a period of positive growth during the COVID-19 pandemic. Owing to rise in the COVID-19 cases, various coagulation parameters such as the platelet count, fibrinogen, D-dimmer, prothrombin time (PT), activated partial thromboplastin time (aPTT), were found as a complication among the patients that were severely infected, thus extensive applications pertaining to plasma therapies were given. The convalescent plasma therapy is used in patients that got infected due to COVID-19. Moreover, as per the article published in the Lancet Journal, between May 28, 2020 and June 15, 2022, 11558 (71%) of 16287 patients enrolled in recovery were eligible to receive convalescent plasma. CP therapy involves the collection of plasma from the patient's body who has recently recovered from infection and infusion of that collected plasma into the body of the individuals that are at a risk. Thus, all these factors had positively impacted the growth of the global apheresis market during the pandemic.

With large number of masses being vaccinated and with the resumption of activities across industries including the healthcare sector, the apheresis market is further expected to grow positively during the forecast period from 2024-2030.

Apheresis Market Segment Analysis:

Apheresis Market by Product Type (Apheresis machines and Disposables), Technology (Centrifugation and Membrane filtration), Procedure (Leukapheresis, Plasmapheresis, Plateletpheresis, Erythrocytapheresis, and Others), Application (Renal Disorders, Hematological Disorders, Neurological Disorders, Autoimmune Disorders and Others), Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Based on the product type segment of the apheresis market, the disposables category is projected to register a significant growth in revenue and was valued at USD 1,376.18 million in 2022 and will grow at a CAGR of 8.26% during the forecast period (2022-2028) to reach USD 2,204.25 million by 2030.

This can be can be attributed to the increased consumption of disposables in the process of apheresis. The disposables present in apheresis machines are manufactured and designed exclusively for one-time use, in order to ensure contamination-free transfer of blood components and maintain sterile conditions. Disposables form a key component for any apheresis system to deliver quality treatment, because of which all the key market players ensure a strong disposable kit profile for their apheresis systems. The Plasmat Futura Kit from B. Braun Melsungen AG, LIFE 21? and LIFE 18(TM) apheresis units disposables from Miltenyi Biotec, disposable TPE 2000 Set for PRISMAFLEX System from Baxter are some of the examples of quality disposables manufactured by key companies in order to build and flourish their market for apheresis.

In addition, recent developments by big market players in order to expand their expertise to more advanced disposable systems is further expected to boost the demand for disposables. For example, in January 2020, Fresenius Kabi AG inaugurated the expansion of the company's production site in Dominican Republic, having advanced production equipment, plasma kit assembly lines and sterilization units, enabling the company to meet the rising demand for high-quality disposables.

Hence, the interplay of all the aforementioned factors is anticipated to propel the market for disposables in the upcoming years.

North America is expected to dominate the overall Apheresis Market:

Among all the regions, North America is expected to lead in revenue generation in the global apheresis market and was valued at USD 979.12 million in 2022. It will grow at a CAGR of 8.44% during the forecast period from 2024 to 2030 to reach USD 1,584.64 million by 2030.

This domination is due to the rising prevalence of chronic diseases and cancers in the region. Moreover, the increase in the number of complex surgical procedures and the rising demand for blood components will also aid in the growth of apheresis market in the North America region.

According to the figures provided by American Cancer Society 2022, it is estimated that there will be nearly 60,650 news cases of leukemia in the year 2023 in the United States. As per the National Cancer Institute 2022, in the year 2019, there were an estimated 472,714 people living with leukemia in the United States. The above statics clearly indicates that the incidence of leukemia is surging every year.

White blood cell reduction apheresis is primarily used as a treatment for patients with leukemia whose blood white cell counts are excessively high. Thus, the increasing prevalence of leukemia in the United Sates will increase the demand of apheresis in the market.

The American Association for the Surgery of Trauma reports that in the United States, injury accounts for over 150,000 deaths and over 3 million non-fatal injuries per year. The injuries undergo some sort of surgical procedure for its treatment or management. Surgical procedure are usually accompanied with blood or blood components transfusion and the blood components can be separated and stored with the aid of apheresis. Therefore, the increasing number of injuries will shoot up the number of surgical procedures, thereby increasing the demand of blood component transfusion, henceforth propelling the demand for apheresis in the market.

Therefore, along with the presence of large number of geriatric patients prone to chronic disorders in North America and the increasing focus of manufacturers on launching new products in the market is expected to bolster the growth of the apheresis market in the overall North America region during the forecast period.

Apheresis Market Key Players:

Some of the key market players operating in the apheresis market include Braun Melsungen AG, Asahi Kasei Corporation, Fresenius Kabi AG, Haemonetics Corporation, Terumo Corporation, Baxter International, Kaneka Corporation, Sumitomo Bakelite Company Limited, Medica SPA, Nikkiso Co., Ltd., Cerus Corporation, Miltenyi Biotec B.V & Co., KG, Haier Inc., Otsuka Holdings and others.

Recent Developmental Activities in Apheresis Market:

In June 2022, Terumo, a medical technology company, announces that the UK's NHS England has selected the Spectra OptiaR Apheresis System through the NHS MedTech Funding Mandate to treat sickle cell disease. As a result, Spectra Optia will be deployed more widely in hospitals across England.

In May 2022, Terumo, a medical technology company, announces that the UK's NHS England has selected the Spectra OptiaR Apheresis System through the NHS MedTech Funding Mandate to treat sickle cell disease. As a result, Spectra Optia will be deployed more widely in hospitals across England.

In January 2020, Fresenius Kabi unveiled Euro 30 million expansion of transfusion and apheresis disposables plant in Dominican Republic. The top government and company officials joined local executives and employees for the company's production site in the Dominican Republic.

Key Takeaways from the Apheresis Market Report Study

• Market size analysis for current apheresis market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the apheresis market.
• Top key product/services/technology developments, mergers, acquisitions, partnerships, joint ventures happened for last 3 years
• Key companies dominating the global apheresis market.
• Various opportunities available for the other competitor in the apheresis market space.
• What are the top performing segments in 2023? How these segments will perform in 2030.
• Which is the top-performing regions and countries in the current apheresis market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for apheresis market growth in the coming future?

Target Audience who can be benefited from this Apheresis Market Report Study

• Apheresis products providers
• Research organizations and consulting companies
• Apheresis-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in apheresis machines and disposables
• Various end users who want to know more about the apheresis market and latest technological developments in the apheresis market.

Frequently Asked Questions for Apheresis Market:

1. What is apheresis?

Apheresis is a medical technology used to separate various constituents of the blood, in which the remaining components of the blood are returned to the patient after extraction of the desired component (viz. erythrocytes, leukocytes, plasma, platelets etc.).

2. What is the market for the global Apheresis?

The global apheresis market was valued at USD 2,230.66 million in 2022 and is estimated to grow at a CAGR of 8.75% during the forecast period (2022-2028) to reach USD 3,671.55 million by 2030.

3. What are the drivers for the global Apheresis market?

The apheresis market is slated to witness prosperity owing to factors such as the increasing prevalence of hematological disorders such as sickle cell, anemia, blood cancers among others, the rise in the requirement of source plasma by various biopharmaceutical companies and an increase in the launch and approval of apheresis systems during the forecast period (2024-2030).

4. Who are the key players operating in the global Apheresis market?

Some of the key market players operating in the Apheresis market include Braun Melsungen AG, Asahi Kasei Corporation, Fresenius Kabi AG, Haemonetics Corporation, Terumo Corporation, Baxter International, Kaneka Corporation, Sumitomo Bakelite Company Limited, Medica SPA, Nikkiso Co., Ltd., Cerus Corporation, Miltenyi Biotec B.V & Co., KG, Haier Inc., Otsuka Holdings and others.

5. Which region has the highest share in the Apheresis market?

North America is expected to dominate the overall apheresis market during the forecast period, 2024 to 2030. This can be ascribed to the rising prevalence of chronic diseases and cancers in the region. Moreover, the increase in the number of complex surgical procedures and the rising demand for blood components will also aid in the growth of the apheresis market in the North America region.

Table of Contents

1.Apheresis Market Report Introduction

2.Apheresis Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment

3. Regulatory Analysis

• 3.1. The United States
• 3.2. Europe
• 3.3. Japan
• 3.4. China

4. Apheresis Market Key Factors Analysis

• 4.1. Apheresis Market Drivers
  • 4.1.1. Increasing prevalence of hematological disorders
  • 4.1.2. Rising demand of source plasma from biopharmaceutical companies.
  • 4.1.3. Favorable reimbursement policies and funding associated with apheresis procedures
• 4.2. Apheresis Market Restraints and Challenges
  • 4.2.1. High cost involved in apheresis treatment
  • 4.2.2. Risks associated with the apheresis treatment
• 4.3. Apheresis Market Opportunities
  • 4.3.1. Surge in innovation and R&D for new apheresis treatment methods, specially designed for children
  • 4.3.2. Reduction in the cost of lipoprotein apheresis and widespread availability of the therapy.

5. Apheresis Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Apheresis Market

7. Apheresis Market Layout

• 7.1. By Product Type
  • 7.1.1. Apheresis machines
  • 7.1.2. Disposables
• 7.2. By Technology
  • 7.2.1. Centrifugation
  • 7.2.2. Membrane filtration
• 7.3. By Procedure
  • 7.3.1. Leukapheresis
  • 7.3.2. Plasmapheresis
  • 7.3.3. Plateletpheresis
  • 7.3.4. Erythrocytapheresis
  • 7.3.5. Others
• 7.4. By Application
  • 7.4.1. Renal Disorders
  • 7.4.2. Hematological Disorders
  • 7.4.3. Neurological Disorders
  • 7.4.4. Autoimmune Disorders
  • 7.4.5. Others
• 7.5. By Geography
  • 7.5.1. North America
    • 7.5.1.1. United States Apheresis Market in USD million (2021-2030)
    • 7.5.1.2. Canada Apheresis Market in USD million (2021-2030)
    • 7.5.1.3. Mexico Apheresis Market in USD million (2021-2030)
  • 7.5.2. Europe
    • 7.5.2.1. France Apheresis Market in USD million (2021-2030)
    • 7.5.2.2. Germany Apheresis Market in USD million (2021-2030)
    • 7.5.2.3. United Kingdom Apheresis Market in USD million (2021-2030)
    • 7.5.2.4. Italy Apheresis Market in USD million (2021-2030)
    • 7.5.2.5. Spain Apheresis Market in USD million (2021-2030)
    • 7.5.2.6. Rest of Europe Apheresis Market in USD million (2021-2030)
  • 7.5.3. Asia-Pacific
    • 7.5.3.1. China Apheresis Market in USD million (2021-2030)
    • 7.5.3.2. Japan Apheresis Market in USD million (2021-2030)
    • 7.5.3.3. India Apheresis Market in USD million (2021-2030)
    • 7.5.3.4. Australia Apheresis Market in USD million (2021-2030)
    • 7.5.3.5. South Korea Apheresis Market in USD million (2021-2030)
    • 7.5.3.6. Rest of Asia Pacific Apheresis Market in USD million (2021-2030)
  • 7.5.4. Rest of the World (RoW)
    • 7.5.4.1. Middle East Apheresis Market in USD million (2021-2030)
    • 7.5.4.2. Africa Apheresis Market in USD million (2021-2030)
    • 7.5.4.3. South America Apheresis Market in USD million (2021-2030)

8. Apheresis Market Global Company Share Analysis - Key 3-5 Companies

9. Apheresis Market Company and Product Profiles

• 9.1. Braun Melsungen AG
  • 9.1.1. Company Overview
  • 9.1.2. Company Snapshot
  • 9.1.3. Financial Overview
  • 9.1.4. Product Listing
  • 9.1.5. Entropy
• 9.2. Asahi Kasei Corporation
  • 9.2.1. Company Overview
  • 9.2.2. Company Snapshot
  • 9.2.3. Financial Overview
  • 9.2.4. Product Listing
  • 9.2.5. Entropy
• 9.3. Fresenius Kabi AG
  • 9.3.1. Company Overview
  • 9.3.2. Company Snapshot
  • 9.3.3. Financial Overview
  • 9.3.4. Product Listing
  • 9.3.5. Entropy
• 9.4. Haemonetics Corporation
  • 9.4.1. Company Overview
  • 9.4.2. Company Snapshot
  • 9.4.3. Financial Overview
  • 9.4.4. Product Listing
  • 9.4.5. Entropy
• 9.5. Terumo Corporation
  • 9.5.1. Company Overview
  • 9.5.2. Company Snapshot
  • 9.5.3. Financial Overview
  • 9.5.4. Product Listing
  • 9.5.5. Entropy
• 9.6. Baxter International
  • 9.6.1. Company Overview
  • 9.6.2. Company Snapshot
  • 9.6.3. Financial Overview
  • 9.6.4. Product Listing
  • 9.6.5. Entropy
• 9.7. Kaneka Corporation
  • 9.7.1. Company Overview
  • 9.7.2. Company Snapshot
  • 9.7.3. Financial Overview
  • 9.7.4. Product Listing
  • 9.7.5. Entropy
• 9.8. Sumitomo Bakelite Company Limited
  • 9.8.1. Company Overview
  • 9.8.2. Company Snapshot
  • 9.8.3. Financial Overview
  • 9.8.4. Product Listing
  • 9.8.5. Entropy
• 9.9. Medica SPA
  • 9.9.1. Company Overview
  • 9.9.2. Company Snapshot
  • 9.9.3. Financial Overview
  • 9.9.4. Product Listing
  • 9.9.5. Entropy
• 9.10. Nikkiso Co., Ltd.
  • 9.10.1. Company Overview
  • 9.10.2. Company Snapshot
  • 9.10.3. Financial Overview
  • 9.10.4. Product Listing
  • 9.10.5. Entropy
• 9.11. Cerus Corporation
  • 9.11.1. Company Overview
  • 9.11.2. Company Snapshot
  • 9.11.3. Financial Overview
  • 9.11.4. Product Listing
  • 9.11.5. Entropy
• 9.12. Miltenyi Biotec B.V. & Co. KG
  • 9.12.1. Company Overview
  • 9.12.2. Company Snapshot
  • 9.12.3. Financial Overview
  • 9.12.4. Product Listing
  • 9.12.5. Entropy
• 9.13. Haier Inc.
  • 9.13.1. Company Overview
  • 9.13.2. Company Snapshot
  • 9.13.3. Financial Overview
  • 9.13.4. Product Listing
  • 9.13.5. Entropy
• 9.14. Otsuka Holdings
  • 9.14.1. Company Overview
  • 9.14.2. Company Snapshot
  • 9.14.3. Financial Overview
  • 9.14.4. Product Listing
  • 9.14.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us